Eli Lilly and Company (NYSE:LLY) Trading Up 1.5% – Here’s Why

Posted by Brian Himes on Jul 1st, 2026

Eli Lilly and Company logo Eli Lilly and Company (NYSE:LLY – Get Free Report) shares were up 1.5% during trading on Monday . The stock traded as high as $1,238.00 and last traded at $1,226.2240. Approximately 3,651,909 shares traded hands during mid-day trading, an increase of 13% from the average daily volume of 3,230,916 shares. The stock had previously closed at $1,208.12.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

Positive Sentiment: Analysts remain constructive on Eli Lilly, with one 24/7 Wall St. note projecting double-digit upside and pointing to continued strength in Lilly’s GLP-1 franchise and its broader growth runway. Eli Lilly Price Prediction: The Case for Double-Digit Upside
Positive Sentiment: Lilly and Innovent announced a China commercialization agreement for Verzenios (abemaciclib), which could expand access to Lilly’s breast cancer treatment in mainland China while Lilly keeps manufacturing and supply responsibilities. Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China
Positive Sentiment: Several analyst and media reports highlighted Lilly’s continued momentum in obesity and diabetes drugs, with commentary suggesting the GLP-1 growth story and upcoming catalysts remain intact. Several Analysts Pounds the Table on Eli Lilly Stock (LLY) Heading into Earnings
Neutral Sentiment: Media coverage also pointed to Lilly’s expanding international footprint and pipeline innovation, including commentary on retatrutide, manufacturing readiness, and a new leadership appointment in Romania. These items support the long-term story but are less likely to move the stock immediately.
Negative Sentiment: China-related headline risk is weighing on sentiment after reports that Hybio filed what may be the first generic challenge against Lilly’s tirzepatide patents, raising concerns about future exclusivity in a key growth market. China’s Hybio Challenges Eli Lilly Patents With First Generic Filing for Blockbuster Weight-Loss Drug Tirzepatide
Negative Sentiment: U.S. lawmakers have opened a probe into Lilly’s China trial practices, asking for details on oversight and data access, which adds regulatory and geopolitical uncertainty. Eli Lilly (LLY) Faces China Trial Security Probe From U.S. Lawmakers

Analyst Ratings Changes

A number of research analysts have issued reports on LLY shares. Wall Street Zen upgraded Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 2nd. UBS Group reissued a “buy” rating on shares of Eli Lilly and Company in a report on Wednesday, March 18th. The Goldman Sachs Group restated a “buy” rating and set a $1,283.00 price objective on shares of Eli Lilly and Company in a research note on Friday, May 22nd. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $1,285.00 price objective on shares of Eli Lilly and Company in a report on Friday, March 6th. Finally, Weiss Ratings cut shares of Eli Lilly and Company from a “buy (b)” rating to a “buy (b-)” rating in a research note on Tuesday, May 19th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $1,235.07.

View Our Latest Research Report on Eli Lilly and Company

Eli Lilly and Company Trading Down 0.6%

The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. The stock has a market capitalization of $1.12 trillion, a P/E ratio of 42.35, a PEG ratio of 1.35 and a beta of 0.53. The firm’s 50-day simple moving average is $1,048.18 and its 200 day simple moving average is $1,024.30.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last released its earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating the consensus estimate of $6.97 by $1.58. The business had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The business’s quarterly revenue was up 55.5% on a year-over-year basis. During the same period in the prior year, the business earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities research analysts anticipate that Eli Lilly and Company will post 35.74 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be issued a dividend of $1.73 per share. The ex-dividend date is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s payout ratio is currently 24.58%.

Institutional Investors Weigh In On Eli Lilly and Company

Hedge funds have recently bought and sold shares of the business. Maryland Capital Advisors Inc. purchased a new stake in Eli Lilly and Company in the 4th quarter worth approximately $25,000. Osbon Capital Management LLC acquired a new position in shares of Eli Lilly and Company in the fourth quarter worth $25,000. Vermillion & White Wealth Management Group LLC raised its holdings in shares of Eli Lilly and Company by 84.2% during the third quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock worth $27,000 after acquiring an additional 16 shares in the last quarter. Basso Capital Management L.P. purchased a new stake in shares of Eli Lilly and Company during the fourth quarter worth $30,000. Finally, 10Elms LLP boosted its position in Eli Lilly and Company by 33.3% during the third quarter. 10Elms LLP now owns 40 shares of the company’s stock valued at $31,000 after purchasing an additional 10 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

About Eli Lilly and Company

(Get Free Report)

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.